Roche Holding Ltd. (ADR) (NASDAQOTH:RHHBY)

CAPS Rating: 5 out of 5

Results 1 - 20 of 23 : 1 2 Next »

Recs

1
Member Avatar jb2un (25.45) Submitted: 12/14/2013 3:12:25 PM : Outperform Start Price: $33.21 RHHBY Score: -1.62

Has a great pipeline of cancer drugs

Recs

0
Member Avatar Gdgollymsmolly (< 20) Submitted: 12/5/2013 6:53:15 PM : Outperform Start Price: $33.73 RHHBY Score: -3.90

Great pipeline, good Hep C drug nearing approval.

Recs

1
Member Avatar mchedester (71.46) Submitted: 3/11/2013 5:12:48 AM : Outperform Start Price: $27.34 RHHBY Score: +3.32

I don't know why this biotech is so grossly undervalued. I think it is because it is not an American company. But the p/e is well below industry average and the good news about pipeline and approvals just keep pouring in.

Recs

1
Member Avatar Fish08 (64.66) Submitted: 12/10/2012 2:27:08 PM : Outperform Start Price: $23.87 RHHBY Score: +11.11

Leads in biotech, diagnostic products for hospitals, cancer therapies as well as many tiny markets. PE = 15, 3.8% yield.

Recs

1
Member Avatar CKRhea12 (< 20) Submitted: 2/26/2012 8:48:09 PM : Outperform Start Price: $20.18 RHHBY Score: +32.91

With its probably acquisition of Illumina, Roche will be well positioned to revolutionize the healthcare industry by reaching a new level of personalized treatment. Using its "two-pillared" structure (pharma and dx divisions support one another), Roche intends to use the new sequencing technology to discover new biomarkers for diseases and cancers. With these biomarkers they can then develop pharmaceuticals like monoclonal antibodies (which they already are a global leader in thanks to Genentech) that attack the diseased genes/cells directly instead of every cell. Think of it as going from a bombing run to a smart missile when it comes to treatment. It will make the diagnostics more accurate and treatment more effective (not to mention eliminate a lot of the side effects related to chemotherapy).

Recs

3
Member Avatar colddrink73 (93.78) Submitted: 2/13/2012 12:02:14 PM : Outperform Start Price: $20.63 RHHBY Score: +27.90

Real $ play. The upcoming dividend will give you a 4% return. Since they pay out yearly instead of quartly you only need to have this on the record date to be eligible for the dividend.
Unless I am missing something which is very possible.
I still need to do a bit of research but if this is accurate I don't see the down side.

g

Recs

2
Member Avatar utri (< 20) Submitted: 6/26/2011 7:10:34 AM : Outperform Start Price: $18.99 RHHBY Score: +33.59

-Low PE
-Good dividend yield
-Paying back debt
-Recent acquisitions will create shareholder value.

Recs

2
Member Avatar rofgile (99.42) Submitted: 6/4/2011 11:03:34 AM : Outperform Start Price: $19.72 RHHBY Score: +28.61

While the pharma sales were a bit poorer, their other side of business in reagents/diagnostics/etc is growing rapidly. And their DNA sequencing businesses have great potential in medicine.

Recs

2
Member Avatar jhuangwithnmr (85.99) Submitted: 1/20/2011 2:01:22 PM : Outperform Start Price: $16.12 RHHBY Score: +69.92

Barron's Roundtable 2011 - Abby Joseph Cohen's pick

Recs

2
Member Avatar jcpalmer (< 20) Submitted: 7/16/2010 3:51:16 PM : Outperform Start Price: $15.22 RHHBY Score: +51.24

Purchase of Genentech gives Roche big part of cancer market. Only about 15% of products go off patent in the next two years. P/E of 13 is cheap.

Recs

2
Member Avatar DavidBear (< 20) Submitted: 3/8/2010 9:23:06 AM : Outperform Start Price: $18.62 RHHBY Score: +19.44

They have a leading understanding about personalized medicine

Recs

5
Member Avatar joshbk (65.42) Submitted: 12/22/2009 12:06:43 AM : Outperform Start Price: $18.84 RHHBY Score: +12.70

It might be going a bit far to call them the Google of biotech, but Roche is positioning themselves well to remain an industry leader well into the future. Their success depends more on the future of biotech than on any specific product. Obviously stay away if you think biotech has a bleak future - and between current health care reform, a slow FDA, ect - that just may be the case. But on the other hand, it's hard to see biotech succeeding and Roche failing at the same time.

Recs

0
Member Avatar Hopper39 (34.94) Submitted: 5/6/2009 12:36:11 AM : Outperform Start Price: $14.14 RHHBY Score: +36.03

Should get a nice bump from FDA accelerated approval of Avastin's use on patients with glioblastoma brain cancer. Short-term play.

Recs

0
Member Avatar yaacovm (38.36) Submitted: 4/30/2009 1:38:03 PM : Outperform Start Price: $13.94 RHHBY Score: +28.92

TAMYflu

Recs

0
Member Avatar Pitoburo (< 20) Submitted: 4/28/2009 8:10:09 AM : Outperform Start Price: $14.13 RHHBY Score: +18.15

Pharma will gain thanks to flu

Recs

0
Member Avatar Wokulski (41.65) Submitted: 4/27/2009 5:20:26 PM : Outperform Start Price: $14.13 RHHBY Score: +18.15

swine flu!

Recs

0
Member Avatar ultimategirl1963 (61.95) Submitted: 4/27/2009 8:28:21 AM : Outperform Start Price: $14.07 RHHBY Score: +21.45

weird virus on the rise...watch sales rise ...

Recs

0
Member Avatar Josher429 (< 20) Submitted: 4/26/2009 3:56:05 PM : Outperform Start Price: $14.07 RHHBY Score: +21.45

swine flu

Recs

0
Member Avatar climate (68.07) Submitted: 3/9/2009 2:29:29 PM : Underperform Start Price: $12.61 RHHBY Score: +12.02

leverage buyout at wrong time

Recs

0
Member Avatar pilarcity (< 20) Submitted: 1/18/2008 7:39:36 AM : Outperform Start Price: $19.64 RHHBY Score: +28.07

Very strong marketed products and excellent pipeline.

Results 1 - 20 of 23 : 1 2 Next »

Featured Broker Partners


Advertisement